Interestingly, thefrequencies of CMV-specific CD8+ T cells in the 50CMV-seropositive MS patients did not differ significantly from those of the 36CMV-seropositive healthy subjects, either in the PBMC (P=0.724)(Figure 3d) or within the totalCD8+ population, whereas in these CMV-seropositive subgroupsthe frequency of EBV-lytic-specific CD8+ T cells in the PBMC wasstill significantly lower in the MS patients than in the healthy subjects(P=0.021). Here, CD8A is linked to myeloid sarcoma.